Principia Biopharma Inc.

Principia Biopharma Inc., a late-stage biopharmaceutical company, focuses on developing novel therapies for immune-mediated diseases. The company developing rilzabrutinib, an inhibitor that is in Phase III clinical trials for the treatment of pemphigus, a chronic skin disease, as well as and pemphigus foliaceus; in a Phase 1/2 trial for the treatment of immune thrombocytopenia; and a Phase 2 trial for the treatment of IgG4-related disease. It is also developing PRN2246/SAR442168, an inhibitor, which is in Phase Ii clinical trial for treating multiple sclerosis (MS) and other central nervous systems (CNS) diseases; and PRN473, a drug candidate that is in Phase I clinical trial for the treatment of immune-mediated diseases. The company has a collaboration agreement with Genzyme Corporation to develop relapsing and progressive MS and other diseases of the CNS. Principia Biopharma Inc. was incorporated in 2008 and is based in South San Francisco, California. As of September 25, 2020, Principia Biopharma Inc. operates as a subsidiary of Sanofi.